S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption

Beam Therapeutics (BEAM) Stock Forecast & Price Target

$39.84
+0.35 (+0.89%)
(As of 03/1/2024 ET)

Beam Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$39.18
-1.65% Downside
High Forecast$57.00
Average Forecast$39.18
Low Forecast$20.00
TypeCurrent Forecast
3/4/23 to 3/3/24
1 Month Ago
2/2/23 to 2/2/24
3 Months Ago
12/4/22 to 12/4/23
1 Year Ago
3/4/22 to 3/4/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
6 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$39.18$43.92$48.80$76.33
Predicted Upside-1.65% Downside56.45% Upside70.08% Upside62.89% Upside
Get Beam Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.


BEAM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BEAM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Beam Therapeutics Stock vs. The Competition

TypeBeam TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside-1.65% Downside1,799.06% Upside6.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/28/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$26.00 ➝ $42.00-6.50%
2/28/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$27.00 ➝ $35.00-20.87%
2/27/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$48.00 ➝ $57.00+26.47%
1/29/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$38.00 ➝ $40.00+64.68%
12/15/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$35.00+17.49%
12/8/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$75.00 ➝ $30.00+4.35%
10/31/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/20/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/20/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Bienkowski
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
10/20/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$75.00 ➝ $20.00+8.93%
8/9/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$46.00 ➝ $47.00+80.01%
8/9/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $56.00+113.33%
3/21/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$37.00+14.80%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:12 PM ET.












BEAM Price Target - Frequently Asked Questions

What is Beam Therapeutics's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Beam Therapeutics stock is Hold based on the current 9 hold ratings and 4 buy ratings for BEAM. The average twelve-month price prediction for Beam Therapeutics is $39.18 with a high price target of $57.00 and a low price target of $20.00. Learn more on BEAM's analyst rating history.

Do Wall Street analysts like Beam Therapeutics more than its competitors?

Analysts like Beam Therapeutics less than other Medical companies. The consensus rating for Beam Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how BEAM compares to other companies.

Is Beam Therapeutics being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, Beam Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.

Does Beam Therapeutics's stock price have much upside?

According to analysts, Beam Therapeutics's stock has a predicted upside of 24.31% based on their 12-month stock forecasts.

What analysts cover Beam Therapeutics?

Beam Therapeutics has been rated by Bank of America, Barclays, Jefferies Financial Group, JPMorgan Chase & Co., Royal Bank of Canada, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BEAM) was last updated on 3/3/2024 by MarketBeat.com Staff